Gilead Sciences

Live  

Gilead Sciences is an American biopharmaceutical company that focuses on the development and commercialization of innovative medicines for the treatment of life-threatening diseases. The company was founded in 1987 and is headquartered in Foster City, California.
Gilead Sciences is known for its groundbreaking work in the field of HIV/AIDS. In 1996, the company launched its first HIV medication, Viread, which was the first of its kind to be approved by the US Food and Drug Administration (FDA). Since then, Gilead has developed and commercialized other HIV medications, including Truvada, Atripla, and Biktarvy.
In addition to its work in HIV/AIDS, Gilead Sciences has expanded into other areas of medicine, including hepatitis C, liver diseases, and oncology. In 2017, the company acquired Kite Pharma, a leader in the development of personalized cancer therapies, further diversifying its portfolio.
Gilead Sciences has a global presence, with operations in North America, Europe, Asia, and Latin America. The company currently employs over 12,000 people worldwide and has a market capitalization of over $90 billion.
In recent years, Gilead Sciences has faced criticism for the high prices of its medications, particularly for its HIV and hepatitis C treatments. The company has implemented various initiatives to increase access to its medicines for patients in need, including partnerships with generic drug manufacturers and patient assistance programs.

Gilead Sciences is a company that focuses on making medicines, especially for serious diseases like HIV, liver problems, and some types of cancer. Imagine Gilead as a superhero that creates special potions to help people feel better and live healthier lives.
The way Gilead makes money is by creating these medicines and then selling them to hospitals and pharmacies. Doctors use these medicines to help patients get better, and the hospitals pay Gilead for the drugs. Sometimes, they also work with big research groups to discover new medicines, and this can bring in even more money.
Gilead is successful for a few reasons. First, they invest a lot of time and money into research to find new treatments. This means they’re always trying to create better and more effective medicines. Second, they have strong patents, which are like protective shields that keep other companies from copying their drugs for a certain number of years. This helps them sell their medicines without much competition. Lastly, as more people around the world need healthcare and better treatments, Gilead is well-positioned to help them, which means they will likely continue to be successful in the future.
In summary, Gilead Sciences is good at making medicines that help fight big illnesses, they know how to make money by selling those medicines, and they have the skills and plans to remain a strong player in the healthcare industry for years to come.

R2lsZWFkIF NjaWVuY2Vz IGlzIGEgYm lvcGhhcm1h Y2V1dGljYW wgY29tcGFu eSB0aGF0IG lzIHBhcnRp Y3VsYXJseS Bub3RhYmxl IGZvciBzZX ZlcmFsIHJl YXNvbnMuIE ZpcnN0LCBp dCBoYXMgYS BzdHJvbmcg Zm9jdXMgb2 4gYW50aXZp cmFsIGRydW dzLCBlc3Bl Y2lhbGx5IH Rob3NlIHVz ZWQgdG8gdH JlYXQgaW5m ZWN0aW9ucy BsaWtlIEhJ Vi9BSURTLC BoZXBhdGl0 aXMgQiwgaG VwYXRpdGlz IEMsIGFuZC BpbmZsdWVu emEuIEdpbG VhZCBpcyB3 aWRlbHkgcm Vjb2duaXpl ZCBmb3IgaX RzIGRldmVs b3BtZW50IG 9mIHJldm9s dXRpb25hcn kgSElWIG1l ZGljYXRpb2 5zIGFuZCB0 cmVhdG1lbn RzIGZvciBo ZXBhdGl0aX MgQyB0aGF0 IGhhdmUgc2 lnbmlmaWNh bnRseSBpbX Byb3ZlZCBw YXRpZW50IG 91dGNvbWVz Ljxicj5Bbm 90aGVyIGFz cGVjdCB0aG F0IHNldHMg R2lsZWFkIG FwYXJ0IGlz IGl0cyBjb2 1taXRtZW50 IHRvIHJlc2 VhcmNoIGFu ZCBkZXZlbG 9wbWVudC4g VGhlIGNvbX BhbnkgaW52 ZXN0cyBoZW F2aWx5IGlu IHNjaWVudG lmaWMgaW5u b3ZhdGlvbi wgd2hpY2gg aGFzIGxlZC B0byB0aGUg ZGlzY292ZX J5IG9mIG5l dyB0aGVyYX BpZXMgYW5k IGVuaGFuY2 VtZW50IG9m IGV4aXN0aW 5nIHRyZWF0 bWVudHMuIF RoaXMgZm9j dXMgb24gUi ZhbXA7RCBo YXMgcG9zaX Rpb25lZCBH aWxlYWQgYX MgYSBsZWFk ZXIgaW4gdG hlIGJpb3Bo YXJtYWNldX RpY2FsIHNl Y3Rvci48Yn I+QWRkaXRp b25hbGx5LC BHaWxlYWQg aGFzIG1hZG UgaGVhZGxp bmVzIGZvci BpdHMgcm9s ZSBpbiBhZG RyZXNzaW5n IHB1YmxpYy BoZWFsdGgg Y3Jpc2VzLi BGb3IgZXhh bXBsZSwgZH VyaW5nIHRo ZSBDT1ZJRC 0xOSBwYW5k ZW1pYywgR2 lsZWFkIGRl dmVsb3BlZC ByZW1kZXNp dmlyLCBhbi BhbnRpdmly YWwgZHJ1Zy B0aGF0IGJl Y2FtZSBvbm Ugb2YgdGhl IGZpcnN0IH RyZWF0bWVu dHMgYXV0aG 9yaXplZCBm b3IgdXNlIG FnYWluc3Qg Q09WSUQtMT kuPGJyPlRo ZSBjb21wYW 554oCZcyBi dXNpbmVzcy Btb2RlbCBh bHNvIGluY2 x1ZGVzIGEg Y29tbWl0bW VudCB0byBh Y2Nlc3MgYW 5kIGFmZm9y ZGFiaWxpdH ksIHN0cml2 aW5nIHRvIH Byb3ZpZGUg aXRzIG1lZG ljYXRpb25z IHRvIHBhdG llbnRzIGFy b3VuZCB0aG Ugd29ybGQs IHBhcnRpY3 VsYXJseSBp biBsb3ctIG FuZCBtaWRk bGUtaW5jb2 1lIGNvdW50 cmllcy48Yn I+T3ZlcmFs bCwgR2lsZW FkIFNjaWVu Y2VzIGlzIG Rpc3Rpbmd1 aXNoZWQgYn kgaXRzIGlu bm92YXRpdm UgZHJ1ZyBk ZXZlbG9wbW VudCwgZm9j dXMgb24gY3 JpdGljYWwg dmlyYWwgaW 5mZWN0aW9u cywgYW5kIG l0cyByb2xl IGluIGFkZH Jlc3Npbmcg Z2xvYmFsIG hlYWx0aCBj aGFsbGVuZ2 VzLjxicj4=

VGhlIEdpbG VhZCBTY2ll bmNlcyBjb2 1wYW55J3Mg YnVzaW5lc3 MgbW9kZWwg aXMgZm9jdX NlZCBvbiBk ZXZlbG9waW 5nIGFuZCBj b21tZXJjaW FsaXppbmcg aW5ub3ZhdG l2ZSBtZWRp Y2luZXMgaW 4gYXJlYXMg b2YgaGlnaC B1bm1ldCBt ZWRpY2FsIG 5lZWQuIFRo aXMgaW5jbH VkZXMgY29u ZHVjdGluZy ByZXNlYXJj aCBhbmQgZG V2ZWxvcG1l bnQgZm9yIH RyZWF0bWVu dHMgb2Ygdm lyYWwsIGxp dmVyLCBpbm ZsYW1tYXRp b24sIGFuZC BvbmNvbG9n eSBkaXNlYX Nlcy4gVGhl IGNvbXBhbn kgYWxzbyBz dHJpdmVzIH RvIGltcHJv dmUgYWNjZX NzIHRvIGl0 cyB0aGVyYX BpZXMgZm9y IHBhdGllbn RzIGFyb3Vu ZCB0aGUgd2 9ybGQsIHdo aWxlIG1haW 50YWluaW5n IGEgc3Ryb2 5nIGZpbmFu Y2lhbCBwZX Jmb3JtYW5j ZSBhbmQgZG VsaXZlcmlu ZyB2YWx1ZS B0byBpdHMg c2hhcmVob2 xkZXJzLiBH aWxlYWQncy BhcHByb2Fj aCBpbmNsdW RlcyBjb2xs YWJvcmF0aW 9ucyBhbmQg cGFydG5lcn NoaXBzIHdp dGggb3RoZX IgY29tcGFu aWVzLCBnb3 Zlcm5tZW50 IGFnZW5jaW VzLCBhbmQg bm9uLXByb2 ZpdCBvcmdh bml6YXRpb2 5zLCBhcyB3 ZWxsIGFzIG ludmVzdG1l bnRzIGluIH Jlc2VhcmNo IGFuZCBkZX ZlbG9wbWVu dCB0byBkaX Njb3ZlciBh bmQgZGV2ZW xvcCBuZXcg dHJlYXRtZW 50cyBhbmQg ZXhwYW5kIH RoZSB1c2Ug b2YgaXRzIG V4aXN0aW5n IHByb2R1Y3 RzLg==

AI does pose potential threats to Gilead Sciences, primarily through substitution, disintermediation, and margin pressure, but the extent of these threats is influenced by various factors specific to the pharmaceutical industry.
1. Substitution: AI technologies are advancing rapidly, particularly in drug discovery and development. Machine learning algorithms can analyze vast datasets to identify new drug candidates, which could lead to the development of competing therapies that may replace existing Gilead products. Additionally, AI-driven personalized medicine approaches could tailor treatments more effectively than Gilead’s current offerings, potentially eroding market share if Gilead does not adapt.
2. Disintermediation: AI could change the traditional pharmaceutical supply chain and patient care models. For instance, AI-enabled platforms could facilitate direct connections between drug developers and patients, bypassing traditional distribution channels. This shift could challenge Gilead’s ability to reach customers effectively, reducing the role of established intermediaries like pharmacies and distributors.
3. Margin Pressure: The implementation of AI in healthcare often aims to increase efficiency and reduce costs. If competitors leverage AI to streamline their operations or reduce the costs associated with R&D, they might be able to offer products at lower prices or with higher margins. Gilead may face pressure to lower its own prices or invest in new AI technologies to maintain a competitive position, which can affect profit margins.
Overall, while AI presents various risks to Gilead Sciences, the company’s response, including its investment in AI technologies and its ability to innovate, will play a crucial role in determining the actual impact of these threats on its products, services, and competitive positioning.

Gilead Sciences, like many companies, is affected by changes in interest rates in a few key ways regarding its earnings, cash flow, and valuation.
1. Cost of Borrowing: If interest rates rise, the cost of borrowing increases. Gilead, which may rely on debt for financing operations, acquisitions, or research and development, could face higher interest expenses. This could reduce net income and cash flow from operations.
2. Valuation Impact: Higher interest rates typically result in a higher discount rate used in discounted cash flow models. This can lead to a lower present value of expected future cash flows, thereby impacting the company’s market valuation negatively. Investors may also demand higher rates of return, further compressing the stock price.
3. Investment Decisions: Rising interest rates can lead to a tighter capital environment, potentially impacting Gilead’s ability to invest in new projects or research initiatives. Reduced investment could slow down growth and innovation, affecting long-term earnings potential.
4. Market Sentiment: The biotechnology and pharmaceutical sectors can be sensitive to macroeconomic conditions, including interest rates. If investors anticipate higher rates leading to economic slowdown, it may result in lower stock prices for companies like Gilead, as market sentiment shifts.
5. Cash Flow Management: Changes in interest rates can impact operating cash flows indirectly through shifts in consumer and business spending. If higher rates lead to economic contraction, this may affect sales of Gilead’s products, thus impacting cash flows.
In summary, Gilead Sciences’ earnings, cash flow, and valuation are moderately sensitive to changes in interest rates through borrowing costs, valuation methods, investment capacities, market sentiment, and overall economic conditions.

CiAgICAgIC AgICAgIDxk aXYgc3R5bG U9J3dpZHRo OiAxMDAlOy BkaXNwbGF5 OiBmbGV4Oy BqdXN0aWZ5 LWNvbnRlbn Q6IGNlbnRl cjsnPgogIC AgICAgICAg ICAgICAgPG RpdiBzdHls ZT0nCiAgIC AgICAgICAg ICAgICAgIC AgZGlzcGxh eTogZmxleD sKICAgICAg ICAgICAgIC AgICAgICBh bGlnbi1pdG VtczogY2Vu dGVyOwogIC AgICAgICAg ICAgICAgIC AgIGJhY2tn cm91bmQtY2 9sb3I6ICNm MGY0Zjg7Ci AgICAgICAg ICAgICAgIC AgICAgYm9y ZGVyOiAxcH ggc29saWQg I2QxZTNmMD sKICAgICAg ICAgICAgIC AgICAgICBi b3JkZXItcm FkaXVzOiAx MHB4OwogIC AgICAgICAg ICAgICAgIC AgIHBhZGRp bmc6IDEwcH g7CiAgICAg ICAgICAgIC AgICAgICAg bWFyZ2luOi AyMHB4IDA7 CiAgICAgIC AgICAgICAg ICAgICAgZm 9udC1mYW1p bHk6ICJTZW dvZSBVSSIs IFJvYm90by wgc2Fucy1z ZXJpZjsKIC AgICAgICAg ICAgICAgIC AgICBib3gt c2hhZG93Oi AwIDJweCA2 cHggcmdiYS gwLCAwLCAw LCAwLjA1KT sKICAgICAg ICAgICAgIC AgICAgICBt YXgtd2lkdG g6IDkwMHB4 OwogICAgIC AgICAgICAg ICAgICAgIH dpZHRoOiAx MDAlOyc+Cg ogICAgICAg ICAgICAgIC AgICAgIDxp bWcgc3JjPS Jhc3NldHMv bG9nb3MvQz J6NWNNdGdW ek9UZkxzcG hRWEoud2Vi cCIgYWx0PS JHaWxlYWQg U2NpZW5jZX MiIHRpdGxl PSJHaWxlYW QgU2NpZW5j ZXMiICBjbG Fzcz0iaW1n LWZsdWlkIi BoZWlnaHQ9 OTAgd2lkdG g9OTAgbG9h ZGluZz0nbG F6eScgc3R5 bGU9J2Jvcm Rlci1yYWRp dXM6IDZweD snPgoKICAg ICAgICAgIC AgICAgICAg ICA8ZGl2IH N0eWxlPSdm bGV4OiAxOy B0ZXh0LWFs aWduOiBjZW 50ZXI7IG1h cmdpbi1sZW Z0OiA1cHg7 Jz4KICAgIC AgICAgICAg ICAgICAgIC AgICAgPHAg c3R5bGU9J2 ZvbnQtc2l6 ZTogMjZweD sgY29sb3I6 ICMzMzM7IG 1hcmdpbi1i b3R0b206ID E1cHg7Jz4K ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIPCf k4ggV2FudC B0byByZWFk IG1vcmUgYW JvdXQgR2ls ZWFkIFNjaW VuY2VzPwog ICAgICAgIC AgICAgICAg ICAgICAgIC A8L3A+Cgog ICAgICAgIC AgICAgICAg ICAgICAgIC A8YSBocmVm PSdpbmRleC 5waHA/cGFn ZT1zaWdudX AnIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGJhY2tncm 91bmQtY29s b3I6ICMwMD dCRkY7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBjb2xv cjogI2ZmZj sKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIH BhZGRpbmc6 IDEwcHggMj BweDsKICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgIGJvcmRl ci1yYWRpdX M6IDVweDsK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIHRl eHQtZGVjb3 JhdGlvbjog bm9uZTsKIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgIGZvbn Qtd2VpZ2h0 OiBib2xkOw ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgbW FyZ2luLXJp Z2h0OiAxMH B4OwogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgdHJhbnNp dGlvbjogYm Fja2dyb3Vu ZC1jb2xvci AwLjNzIGVh c2U7JwogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgb25tb3 VzZW92ZXI9 J3RoaXMuc3 R5bGUuYmFj a2dyb3VuZE NvbG9yPSIj MDA1NmIzIi cKICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgIG 9ubW91c2Vv dXQ9J3RoaX Muc3R5bGUu YmFja2dyb3 VuZENvbG9y PSIjMDA3Qk ZGIic+CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBTaWdu IHVwIGZvci BmcmVlCiAg ICAgICAgIC AgICAgICAg ICAgICAgID wvYT4KCiAg ICAgICAgIC AgICAgICAg ICAgICAgID xzcGFuIHN0 eWxlPSdtYX JnaW46IDAg OHB4OyBjb2 xvcjogIzU1 NTsnPm9yPC 9zcGFuPgoK ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGEgaHJl Zj0naW5kZX gucGhwP3Bh Z2U9bG9naW 4nIHN0eWxl PScKICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg IGNvbG9yOi AjMDA3QkZG OwogICAgIC AgICAgICAg ICAgICAgIC AgICAgICAg dGV4dC1kZW NvcmF0aW9u OiB1bmRlcm xpbmU7CiAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgICBmb250 LXdlaWdodD ogNTAwOyc+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgICAgICBs b2cgaW4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PC9hPgoKCi AgICAgICAg ICAgICAgIC AgICAgICAg IDxwIHN0eW xlPSdtYXJn aW4tdG9wOi AxNXB4OyBm b250LXNpem U6IDEzcHg7 IGZvbnQtd2 VpZ2h0OiBi b2xkOyBjb2 xvcjogI2Qz MmYyZjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAg8J +TpSBHZXQg b3VyIGZyZW UgZUJvb2sg bm93OiA8aT 4iVGhlIENo ZWNrbGlzdC BWYWx1ZSBJ bnZlc3Rvci DigJQgQSBT bWFydGVyIF dheSB0byBQ aWNrIFN0b2 NrcyI8L2k+ CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwvcD4K CiAgICAgIC AgICAgICAg ICAgICAgIC AgIDwhLS0K ICAgICAgIC AgICAgICAg ICAgICAgIC AgPGRpdiBz dHlsZT0nbW FyZ2luLXRv cDogMTJweD sgZm9udC1z aXplOiAxM3 B4OyBjb2xv cjogIzQ0ND snPgogICAg ICAgICAgIC AgICAgICAg ICAgICAgIC AgU2lnbiB1 cCBub3cgYW 5kIGdldCBv dXIgZnJlZS BlQm9vayAK ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgIDxi PlRoZSBDaG Vja2xpc3Qg VmFsdWUgSW 52ZXN0b3Ig 4oCUIEEgU2 1hcnRlciBX YXkgdG8gUG ljayBTdG9j a3M8L2I+Ci AgICAgICAg ICAgICAgIC AgICAgICAg IDwvZGl2Pg ogICAgICAg ICAgICAgIC AgICAgICAg ICAtLT4KIC AgICAgICAg ICAgICAgIC AgICAgICAg PCEtLQogIC AgICAgICAg ICAgICAgIC AgICAgICA8 ZGl2IHN0eW xlPSdtYXJn aW4tdG9wOi AxNnB4OyBm b250LXNpem U6IDE0cHg7 IGNvbG9yOi AjNDQ0OyBm b250LWZhbW lseTogLWFw cGxlLXN5c3 RlbSwgQmxp bmtNYWNTeX N0ZW1Gb250 LCBTZWdvZS BVSSwgUm9i b3RvLCBIZW x2ZXRpY2Eg TmV1ZSwgc2 Fucy1zZXJp ZjsgbGluZS 1oZWlnaHQ6 IDEuNjsnPg ogICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgSG F2ZSB5b3Ug aGVhcmQgYW JvdXQgb3Vy IHNob3J0ID xzdHJvbmcg c3R5bGU9J2 ZvbnQtd2Vp Z2h0OiA2MD A7Jz5EYWls eSBWaWRlby BOZXdzbGV0 dGVyPC9zdH Jvbmc+Pwog ICAgICAgIC AgICAgICAg ICAgICAgIC AgICAgPGEg aHJlZj0naH R0cHM6Ly93 d3cuaW5zaW dodGZ1bHZh bHVlLmNvbS 9uZXdzbGV0 dGVyLnBocC cgdGFyZ2V0 PSdfYmxhbm snIHN0eWxl PSdjb2xvcj ogIzAwN0JG RjsgdGV4dC 1kZWNvcmF0 aW9uOiBub2 5lOyBmb250 LXdlaWdodD ogNTAwOyBt YXJnaW4tbG VmdDogNnB4 Oyc+CiAgIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgICAgRm luZCBvdXQg bW9yZQogIC AgICAgICAg ICAgICAgIC AgICAgICAg ICAgPC9hPg ogICAgICAg ICAgICAgIC AgICAgICAg ICA8L2Rpdj 4KICAgICAg ICAgICAgIC AgICAgICAg ICAgLS0+Ci AgICAgICAg ICAgICAgIC AgICAgPC9k aXY+CiAgIC AgICAgICAg ICAgICA8L2 Rpdj4KICAg ICAgICAgIC AgPC9kaXY+ CiAgICAgIC AgICAgIAog ICAgICAgIA ogICAgICAg IDxzcGFuIG NsYXNzPSdi bHVycmVkLX RleHQnPgog ICAgICAgIC AgICBNUzRn UjJsc1pXIE ZrSUZOamFX VnUgWTJWek lIZGhjeSBC bWIzVnVaR1 ZrIElHbHVJ REU1T0QgY2 dZbmtnVFds aiBhR0ZsYk NCU2FXIDl5 WkdGdUxDQm ggSUcxbFpH bGpZVyB3Z1 pHOWpkRzl5 IElHWnliMj BnVG0gVjNJ Rmx2Y21zdS BJRlJvWlNC amIyIDF3WV c1NUlIZGgg Y3lCdVlXMW xaQyBCaFpu UmxjaUIwIG FHVWdZbWxp YkcgbGpZV3 dnYkdGdSBa Q0J2WmlCSG FXIHhsWVdR c0lIZG8gYV dOb0lIZGhj eSBCcmJtOT NiaUJtIGIz SWdhWFJ6SU cgaGxZV3hw Ym1jZyBjSE p2Y0dWeWRH IGxsY3k0OF luSSsgTWk0 Z1IybHNaVy BGa0lGTmph V1Z1IFkyVn pJR2x6SUcg RWdZbWx2Y0 doaCBjbTFo WTJWMWRHIG xqWVd3Z1ky OXQgY0dGdW VTQjBhRyBG MElHWnZZM1 Z6IFpYTWdi MjRnWkcgVj JaV3h2Y0ds dSBaeUJoYm 1RZ1kyIDl0 YldWeVkybG ggYkdsNmFX NW5JSCBSb1 pYSmhjR2xs IGN5Qm1iM0 lnYkcgbG1a UzEwYUhKbC BZWFJsYm1s dVp5IEJrYV hObFlYTmwg Y3l3Z2QybD BhQyBCaElI QmhjblJwIF kzVnNZWEln Wm0gOWpkWE 1nYjI0ZyBT RWxXTDBGSl JGIE1zSUdo bGNHRjAgYV hScGN5QkNJ RyBGdVpDQk RMQ0JzIGFY WmxjaUJrYV ggTmxZWE5s Y3l3ZyBiMj VqYjJ4dloz IGtzSUdGdV pDQnkgWlhO d2FYSmhkRy A5eWVTQmth WE5sIFlYTm xjeTQ4WW4g SStNeTRnVk dobCBJR052 YlhCaGJuIG 5pZ0pseklH WnAgY25OME lHMWhhbSA5 eUlHSnlaV0 ZyIGRHaHli M1ZuYUMgQm pZVzFsSUds dSBJREU1T1 RZZ2QyIGww YUNCMGFHVW cgWVhCd2Nt OTJZVyB3Z2 IyWWdkR2hs IGFYSWdTRW xXSUggUnla V0YwYldWdS BkQ0JrY25W bkxDIEJXYV hKbFlXUXMg SUhkb2FXTm 9JSCBkaGN5 QjBhR1VnIF ptbHljM1Fn ZEggSmxZWF J0Wlc1MCBJ SFJ2SUhSaG NtIGRsZENC aGJpQmwgYm 5wNWJXVWdZ MiBGc2JHVm tJSEpsIGRt VnljMlVnZE ggSmhibk5q Y21sdyBkR0 Z6WlNCMGFH IEYwSUdsek lHVnogYzJW dWRHbGhiQy BCbWIzSWdk R2hsIElISm xjR3hwWTIg RjBhVzl1SU c5bSBJSFJv WlNCSVNWIF lnZG1seWRY TXUgUEdKeV BqUXVJRSBs dUlESXdNVE VzIElFZHBi R1ZoWkMgQl RZMmxsYm1O bCBjeUJoWT NGMWFYIEps WkNCMGFHVW cgWW1sdmNH aGhjbSAxaF kyVjFkR2xq IFlXd2dZMj l0Y0cgRnVl U3dnVUdoaC BjbTFoYzNO bGRDIHdnWm 05eUlDUXgg TVNCaWFXeH NhVyA5dUxp QlVhR2x6IE lHRmpjWFZw YzIgbDBhVz l1SUdKeSBi M1ZuYUhRZ1 IyIGxzWldG a0lIUm8gWl NCaWJHOWph MiBKMWMzUm xjaUJrIGNu Vm5MQ0JUYj MgWmhiR1Jw TENCMyBhR2 xqYUNCeVpY IFp2YkhWMG FXOXUgYVhw bFpDQjBhRy BVZ2RISmxZ WFJ0IFpXNT BJR1p2Y2kg Qm9aWEJoZE dsMCBhWE1n UXk0OFluIE krTlM0Z1Iy bHMgWldGa0 lGTmphVyBW dVkyVnpJR2 hoIGN5QmhJ SE4wY20gOX VaeUJqYjIx dCBhWFJ0Wl c1MElIIFJ2 SUdOdmNuQn YgY21GMFpT QnpiMiBOcF lXd2djbVZ6 IGNHOXVjMm xpYVcgeHBk SGt1SUZSby BaU0JqYjIx d1lXIDU1SU doaGN5Qmsg WlhabGJHOX daVyBRZ1lX NGdZV05qIF pYTnpJSEJ5 YjIgZHlZVz BnZEc4ZyBj SEp2ZG1sa1 pTIEJwZEhN Z2JXVmsgYV dOaGRHbHZi biBNZ2RHOG diRzkzIExX bHVZMjl0Wl MgQmpiM1Z1 ZEhKcCBaWE 1nWVhRZ1pH IGx6WTI5MW JuUmwgWkNC d2NtbGpaWC BNc0lHRnVa Q0JoIGJITn ZJR2hoY3kg QndjbTluY2 1GdCBjeUIw YnlCemRYIE J3YjNKMElH TnYgYlcxMW JtbDBlUyBC aGJtUWdaV1 IxIFkyRjBh Vzl1WVcgd2 dhVzVwZEds aCBkR2wyWl hNdVBHIEp5 UGpZdUlFbH UgSURJd01q QXNJRSBkcG JHVmhaQ0JU IFkybGxibU 5sY3kgQnRZ V1JsSUdobC BZV1JzYVc1 bGN5IEIzYV hSb0lHbDAg Y3lCbGVIQm xjbSBsdFpX NTBZV3dnIF pISjFaeXdn Y20gVnRaR1 Z6YVhacCBj aXdnZDJocF kyIGdnYzJo dmQyVmsgSU hCeWIyMXBj MiBsdVp5Qn laWE4xIGJI UnpJR2x1SU ggUnlaV0Yw YVc1biBJRU 5QVmtsRUxU IEU1SUhCaG RHbGwgYm5S ekxpQlVhRy BVZ1pISjFa eUJ5IFpXTm xhWFpsWkMg QmxiV1Z5Wj JWdSBZM2tn ZFhObElHIE YxZEdodmNt bDYgWVhScG IyNGdabiBK dmJTQjBhR1 VnIFJrUkJJ R0Z1WkMgQm 9ZWE1nYzJs dSBZMlVnWW 1WbGJpIEJr YVhOMGNtbG kgZFhSbFpD QmhjbSA5MW JtUWdkR2hs IElIZHZjbX hrTGogeGlj ajQzTGlCSC BhV3hsWVdR Z1UyIE5wWl c1alpYTWcg YUdGeklHRW daRyBsMlpY SnpaU0IzIG IzSnJabTl5 WTIgVXNJSG RwZEdnZyBa VzF3Ykc5NV pXIFZ6SUda eWIyMGcgYj NabGNpQTJO UyBCamIzVn VkSEpwIFpY TWdZVzVrSU cgRWdiR1Zo WkdWeSBjMm hwY0NCMFpX IEZ0SUcxaF pHVWcgZFhB Z2IyWWdORC BjbElIZHZi V1Z1IExqeG ljajQ0TGkg QlVhR1VnWT I5dCBjR0Z1 ZVNCb1lYIE 1nWVNCemRI SnYgYm1jZ1 oyeHZZbSBG c0lIQnlaWE 5sIGJtTmxM Q0IzYVggUm 9JRzl3WlhK aCBkR2x2Ym 5NZ2FXIDRn VG05eWRHZ2 cgUVcxbGNt bGpZUyB3Z1 JYVnliM0Js IExDQktZWE JoYmkgd2dZ VzVrSUVGei BhV0VnVUdG amFXIFpwWX k0OFluSSsg T1M0Z1IybH NaVyBGa0lG TmphV1Z1IF kyVnpJR2ho Y3kgQmlaV1 Z1SUc1aCBi V1ZrSUc5dV pTIEJ2WmlC MGFHVWcgVj I5eWJHVGln SiBseklFMX ZjM1FnIFFX UnRhWEpsWk MgQkRiMjF3 WVc1cCBaWE 1nWW5rZ1Jt IDl5ZEhWdV pTQk4gWVdk aGVtbHVaUy BCbWIzSWda bTkxIGNpQm piMjV6Wlcg TjFkR2wyWl NCNSBaV0Z5 Y3lBb01qIE F4TnkweU1E SXcgS1M0OF luSStNVCBB dUlFZHBiR1 ZoIFpDQlRZ MmxsYm0gTm xjeUJwY3lC aiBiMjF0YV hSMFpXIFFn ZEc4Z2MzVn ogZEdGcGJt RmlhVyB4cG RIa2dZVzVr IElHaGhjeU J6WlggUWdk R0Z5WjJWMC BjeUIwYnlC eVpXIFIxWT JVZ2RHaGwg YVhJZ1pXNT JhWCBKdmJt MWxiblJoIG JDQnBiWEJo WTMgUXNJR2 x1WTJ4MSBa R2x1WnlCaE lHIGR2WVd3 Z2RHOGcgYz I5MWNtTmxJ RCBFd01DVW djbVZ1IFpY ZGhZbXhsSU cgVnNaV04w Y21saiBhWF I1SUdKNUlE IEl3TWpBZ1 lXNWsgSUhK bFpIVmpaUy BCbmNtVmxi bWh2IGRYTm xJR2RoY3kg QmxiV2x6Yz JsdiBibk1n WW5rZ01qIF VsSUdKNUlE SXcgTWpJdQ ogICAgICAg IDwvc3Bhbj 4KICAgICAg ICAKICAgIC AgICA=